Quick answer: Water reuse in the pharmaceutical industry means recovering non-product water from utilities, cooling and purification systems for reuse, while keeping product-contact water under strict GMP control. Reuse is most feasible for cooling, utilities and RO reject; direct reuse of pharmaceutical-grade water is tightly constrained by regulation.
Key facts – Pharmaceutical water purification rejects a large share of feed water, often 25 to 50 percent at the RO stage, as reusable reject. – Product-contact water (Purified Water, Water for Injection) is governed by pharmacopoeia and GMP standards. – Most feasible reuse is in non-product duties: cooling, utilities, steam and cleaning. – EU GMP Annex 1 and pharmacopoeia monographs set strict quality and control requirements. – Reuse projects require documented risk assessment and often change control under a pharmaceutical quality system.
Brine Consulting is an independent, vendor-neutral advisory. We do not sell equipment or represent suppliers, so this guidance helps you find safe, compliant reuse opportunities, not select a product. This page covers the reuse angle; it does not cover the cost of pharmaceutical wastewater treatment, which is a separate topic.
What does water reuse mean in pharma?
Water reuse in pharma is the recovery of water from one duty for use in another, kept strictly within the quality and compliance limits set by GMP. It reduces intake and effluent without touching product safety.
Pharmaceutical sites produce high-purity water (Purified Water and Water for Injection) using multi-stage purification that rejects a substantial fraction of feed water. That reject, plus cooling and utility streams, is where reuse is most achievable.
The organising principle is separation of product-contact water, which is heavily regulated, from non-product water, where reuse is far more flexible.
Why does water reuse matter in pharma?
Water reuse matters because pharmaceutical purification is water-intensive and much feed water is rejected, while water cost, scarcity and corporate targets rise. Reuse cuts waste without compromising quality.
Drivers include water scarcity and abstraction limits, the cost of purified feed water, corporate sustainability and water-reduction commitments, and pressure to reduce effluent volume. Because so much water is rejected during purification, recovering it is often a clear efficiency gain.
Reuse also improves resilience and can defer expansion of intake and effluent systems.
Where is reuse feasible in pharma?
Reuse is most feasible in non-product duties, where GMP does not directly apply, and least feasible for product-contact water, which is tightly controlled. Feasibility follows the distance from the product.
- RO and purification reject: relatively clean, ideal for cooling make-up, utilities or feed to a lower-grade loop.
- Cooling-tower blowdown: reusable for cleaning, utilities or irrigation after treatment.
- HVAC condensate: clean water suitable for cooling or utility make-up.
- Steam condensate: recoverable energy and water where not product-contact.
- Non-critical cleaning water: reusable in earlier cleaning stages.
- Product-contact water: direct reuse is generally not permitted without exceptional justification.
What are the GMP and regulatory constraints?
The central constraint is that product-contact water must meet pharmacopoeia monographs and GMP, which effectively rules out casual reuse of that water. Non-product water is far less constrained.
Purified Water and Water for Injection must comply with European Pharmacopoeia monographs and be produced and controlled under EU GMP, including the revised Annex 1 for sterile products. These standards govern generation, storage, distribution and monitoring, leaving no room for uncontrolled reuse into product-contact systems. Reuse in non-product duties is acceptable but still requires risk assessment and change control within the pharmaceutical quality system. In the Netherlands, abstraction and discharge are permitted by the water authorities.
How is a pharma reuse project managed?
A pharma reuse project is managed through the quality system: identify non-product opportunities, assess risk, and implement under change control. The steps below outline the approach.
- Map the water system: document product-contact and non-product water and their flows.
- Identify non-product opportunities: target RO reject, cooling and condensate streams.
- Assess risk: confirm reuse cannot cross-contaminate product-contact systems.
- Design segregation: ensure physical and procedural separation from GMP water.
- Treat to the target duty: apply filtration, disinfection or membranes as needed.
- Implement under change control: document the change within the quality system.
- Qualify and monitor: verify performance and maintain ongoing quality checks.
What technologies are used?
Technology choice follows the non-product target duty, since product-contact water is out of scope for reuse. Reject water is often already clean.
| Technology | Role | Typical reuse duty |
|---|---|---|
| Filtration | Removes suspended solids | Cooling make-up, cleaning |
| Softening | Removes hardness | Cooling, boiler feed |
| Ultrafiltration | Removes solids and microorganisms | Utility water |
| Reverse osmosis | Removes dissolved solids | Higher-grade utility loops |
| UV disinfection | Controls microorganisms | Any reuse duty |
| Heat recovery on condensate | Recovers energy and water | Boiler and utility make-up |
RO reject is frequently low in solids and needs only light treatment for cooling or utility reuse.
What does reuse cost and save?
Costs are usually modest for non-product reuse because reject and condensate streams are relatively clean. Savings come from reduced intake, purification feed and effluent.
Main cost drivers are treatment for the target duty, segregated piping and tankage, monitoring, and qualification effort under the quality system. Offsetting savings include lower raw-water purchase and abstraction, reduced load on purification, and lower discharge charges. Recovering RO reject for cooling is often a low-cost, quick win, but figures are site-specific.
Common mistakes to avoid
The most common mistake is treating reuse as a purely technical change and skipping the quality-system route. Others recur across pharmaceutical projects.
- Attempting to reuse into product-contact systems without exceptional justification.
- Omitting risk assessment and change control for non-product reuse.
- Failing to guarantee physical segregation from GMP water.
- Overlooking microbiological control on stored reuse water.
- Choosing technology before confirming the compliance route.
When to bring in an independent advisor
Bring in an independent advisor when reuse touches areas near GMP water, when the compliance route is unclear, or when several vendors offer competing systems. Independent advice keeps reuse firmly on the non-product side and aligned with your quality system.
Because Brine Consulting sells no equipment, our guidance is neutral: where reuse is compliant, how to segregate it, and how to document it within GMP requirements.
Frequently asked questions
Can pharmaceutical-grade water be reused?
Direct reuse of product-contact water such as Purified Water or Water for Injection is generally not permitted, because it must meet pharmacopoeia monographs and GMP at the point of use. Reuse focuses instead on non-product streams. Any exception would require exceptional justification and full validation within the pharmaceutical quality system.
What is the best water to reuse in a pharma plant?
The best candidate is usually RO or purification reject, which is relatively clean and produced in large volume. It suits cooling-tower make-up or utility loops with light treatment. Cooling blowdown, HVAC condensate and steam condensate are also strong candidates, all firmly on the non-product side of the water system.
Does GMP allow water reuse?
GMP does not forbid reuse in non-product duties, but it strictly controls product-contact water. Reuse projects must be assessed for cross-contamination risk, kept segregated from GMP water, and implemented under change control within the quality system. Product-contact water itself remains governed by pharmacopoeia and GMP, leaving no room for uncontrolled reuse.
How much water does pharmaceutical purification waste?
Multi-stage purification rejects a substantial fraction of feed water, often 25 to 50 percent at the RO stage, though this varies by design and feed quality. This reject is relatively clean and is the leading reuse opportunity on many sites. Actual figures should be measured from the specific purification system.
What regulations apply to pharma water in the EU?
Product-contact water must comply with European Pharmacopoeia monographs for Purified Water and Water for Injection and be produced under EU GMP, including Annex 1 for sterile products. These govern generation, storage and monitoring. The EU Water Framework Directive and Dutch abstraction and discharge permits apply to intake and effluent more broadly.
Sources and further reading
- European Directorate for the Quality of Medicines (EDQM), European Pharmacopoeia water monographs
- European Commission, EU GMP including Annex 1
- European Commission, Water Framework Directive
- European Union, Regulation (EU) 2020/741 on minimum requirements for water reuse
- Dutch water authorities (Unie van Waterschappen), abstraction and discharge
Talk to Brine Consulting for an independent, vendor-neutral review of compliant water reuse opportunities on your pharmaceutical site.
Written by the Brine Consulting advisory team. The Brine Consulting advisory practice includes Edwin Muller, a senior industrial water expert with over 25 years across refineries, petrochemicals and power generation, and Cesar J.M. Chu Ortega, a water-tech strategist and electrocoagulation specialist working across textile, chemical and municipal applications. Meet our experts.